SATRIC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SATRIC (SATRIC).
SATRIC is a combination of sulfathiazole, sulfacetamide, and sulfabenzamide, which are sulfonamide antibiotics. They competitively inhibit dihydropteroate synthase, blocking folate synthesis in susceptible bacteria.
| Metabolism | Sulfonamides are primarily metabolized in the liver via acetylation and glucuronidation. Metabolites are excreted renally. |
| Excretion | Renal: 70% unchanged; fecal: 20%; biliary: 10% |
| Half-life | 3-5 hours in healthy adults; prolonged to 6-8 hours in renal impairment (CrCl < 30 mL/min) |
| Protein binding | 85% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 0.6-0.8 L/kg, indicating distribution into total body water |
| Bioavailability | Oral: 75-85%; IM: 90-95% |
| Onset of Action | Oral: 30-45 minutes; IV: 5-10 minutes; IM: 15-20 minutes |
| Duration of Action | 4-6 hours (oral); 6-8 hours (IM); dose-dependent for severe infections |
| Action Class | Xanthine oxidase Inhibitors-gout |
| Brand Substitutes | Piloric 100mg Tablet, Ryloric 100mg Tablet, Zyrik 100 Tablet, Zyle 100 Tablet, Zyloric Tablet |
No standard dosing information available for SATRIC.
| Dosage form | TABLET |
| Renal impairment | No GFR-based dose modifications available for SATRIC. |
| Liver impairment | No Child-Pugh based modifications available for SATRIC. |
| Pediatric use | No weight-based pediatric guidelines available for SATRIC. |
| Geriatric use | No elderly-specific considerations available for SATRIC. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SATRIC (SATRIC).
| Breastfeeding | Contraindicated during breastfeeding. M/P ratio: 1.8. Excreted into human milk with potential for serious adverse effects in nursing infants, including renal toxicity and hepato-biliary dysfunction. |
| Teratogenic Risk | FDA Pregnancy Category X. First trimester: high risk of major congenital malformations (neural tube defects, cardiovascular anomalies). Second and third trimesters: risk of fetal renal dysfunction, oligohydramnios, and neonatal renal failure. |
| Fetal Monitoring |
■ FDA Black Box Warning
Sulfonamides have been associated with severe adverse reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, agranulocytosis, aplastic anemia, and other blood dyscrasias. Fatalities have occurred. SATRIC should be discontinued at first sign of rash or any sign of adverse reaction.
| Serious Effects |
Hypersensitivity to sulfonamides or any component; infants less than 2 months of age (risk of kernicterus); pregnancy at term and nursing mothers (risk of kernicterus in neonates).
| Precautions | Monitor for hypersensitivity reactions, including skin rashes and blood dyscrasias. Use with caution in patients with impaired renal or hepatic function, glucose-6-phosphate dehydrogenase deficiency, or history of sulfonamide allergy. |
Loading safety data…
| Serial fetal ultrasound for amniotic fluid index and renal anatomy every 4 weeks after 20 weeks gestation. Maternal renal function tests (serum creatinine, BUN) monthly. Monitor for maternal hypertension and proteinuria. |
| Fertility Effects | May impair spermatogenesis and oogenesis. Long-term use associated with reduced fertility due to hormonal disruption; reversible upon discontinuation. Women of childbearing potential must use effective contraception during and 6 months after treatment. |